Mesoblast (MESO) Added to Nasdaq Biotechnology Index

Mesoblast Limited (Nasdaq: MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its upcoming addition to the Nasdaq Biotechnology Index (Nasdaq: NBI) as part of the annual reconstitution of the 2024 Nasdaq index. Mesoblast’s inclusion in the NBI will be effective after the U.S. market opens on Monday, December 23, 2024.

The Nasdaq Biotechnology Index contains securities of Nasdaq-listed companies classified according to the Industry Classification Benchmark as either Biotechnology or Pharmaceuticals. The Nasdaq Biotechnology Index is calculated under a modified capitalization-weighted methodology. Companies in the Nasdaq Biotechnology Index must meet eligibility requirements, including minimum market capitalization and average daily trading volume, among other criteria. Nasdaq selects constituents once annually in December.

You May Also Be Interested In

• FDA clears Dexcom's over-the-counter glucose monitor for children
• MicroVision applies to transfer listing to NASDAQ capital market
• Freedom Holding launches $300 million common stock offering